Abstract
Objectives: Pompe disease is a rare genetic disease produced by mutations in the GAA gene leading to progressive skeletal and respiratory muscle weakness. T1-weighted magnetic resonance imaging is useful to identify fatty replacement in skeletal muscles of late-onset Pompe disease (LOPD) patients. Previous studies have shown that replacement by fat correlates with worse results of muscle function tests. Our aim was to investigate if fat replacement of muscles involved in the ventilation process correlated with results of the spirometry and predicted respiratory muscle impairment in LOPD patients over time.Materials and Methods: We studied a cohort of 36 LOPD patients followed up annually in our center for a period of 4 years. We quantified muscle fat replacement using Mercuri score of the thoracic paraspinal and abdominal muscles and the pillars of the diaphragm. We correlated the combined Mercuri scores of these areas with spirometry results and the need of respiratory support.Results: We found a statistically significant correlation (Spearman test, p < 0.05; coefficient of correlation > 0.6) between forced vital capacity seated and lying and fat fraction score of all muscle groups studied. The group of patients who needed respiratory support had higher fat fraction scores than patients not requiring ventilatory support. Higher fat replacement in these areas correlated with worse progression in spirometry values over time.Conclusions: Fat replacement of paraspinal, abdominal, and trunk muscles correlates with results of spirometry and is able to predict worsening in respiratory muscle function tests that could lead to an emerging ventilatory dysfunction. Therefore, the identification of fat replacement in these muscle groups should lead to a closer monitorization of patients. Radiologic evaluation of diaphragm pillars in T1-weighted imaging axial sequences could also be helpful to predict respiratory insufficiency.
Highlights
Pompe disease or glycogen storage disease type II is a rare genetic disease produced by mutations in the GAA gene encoding the enzyme acid alpha glucosidase (AAG)
In late-onset Pompe disease (LOPD), symptoms start in any moment after 1 year old, being characteristic a slowly progressive weakness affecting proximal muscles of the limbs and/or axial muscles associated or not with respiratory muscle involvement and elevated creatine kinase (CK) values in blood tests in most patients [2, 3]
We show that fat replacement of thoracic, abdominal, and paraspinal muscles correlates with low values of forced vital capacity (FVC) percentage predicted both seated and lying in a large cohort of LOPD patients
Summary
Pompe disease or glycogen storage disease type II is a rare genetic disease produced by mutations in the GAA gene encoding the enzyme acid alpha glucosidase (AAG) This enzyme catalyzes glycogen into glucose inside the lysosomes. In infantile-onset Pompe disease, symptoms start during the first months of life and are characterized by hypotonia, general muscle weakness, respiratory impairment, and hypertrophic cardiomyopathy. This phenotype is very severe with an ominous prognosis and is associated with a very low or absent expression of AAG [2]. A single placebo-controlled clinical trials and several open-label studies have already shown the efficacy of ERT maintaining muscle and respiratory function over time [5,6,7,8]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
